Immuron announces new u.s. department of defense research award for naval medical research command and walter reed army institute of research to advance travelan®

Highlights: $3.5 (usd $2.3) million funding for nmrc and wrair approved by the u.s. department of defense to advance the development of travelan. melbourne, australia, aug. 16, 2024 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), an australian based and globally integrated biopharmaceutical company is pleased to announce the funding of a new research agreement for the naval medical research command (nmrc), and walter reed army institute of research (wrair) silver spring, md, usa.
IMRN Ratings Summary
IMRN Quant Ranking